StemRIM and Shionogi Announce Topline Results of Clinical Trials of Redasemtide in Patients with Dystrophic Epidermolysis Bullosa and Acute Ischemic Stroke

Data ReadoutRedasemtideNeutral

AI Analysis

Summary

Shionogi and StemRIM announced topline results from Phase 2 clinical trials of Redasemtide in patients with Dystrophic Epidermolysis Bullosa and Acute Ischemic Stroke. No outcome details were provided in the announcement.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Topline results announced for Phase 2 clinical trials

Importance:6/10

Sentiment:

0.00

rare_diseaseneurologydermatologyclinical_trialtopline_results

Related Companies

$SGIOY

Read the original article

Published by Drugs.com Clinical Trial Results on September 9, 2026 4:09 AM

Read Original